Gene-therapy evidence in monogenic neuromuscular disease

# Evidence Digest: Gene-Therapy Evidence in Monogenic Neuromuscular Disease

Clinical bottom line

Gene therapy has emerged as a promising treatment modality for various monogenic neuromuscular diseases, particularly spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). Recent clinical trials have demonstrated that gene therapy can lead to significant improvements in motor function and overall quality of life in affected patients. However, the long-term efficacy and safety of these therapies remain under investigation, necessitating careful patient selection and monitoring.

What the evidence shows

1. **Spinal Muscular Atrophy (SMA)**: The landmark trial of onasemnogene abeparvovec (Zolgensma) for SMA demonstrated substantial efficacy in infants with the disease. A study by Mendell et al. (2021) reported that treated infants showed significant improvements in motor milestones compared to untreated controls, with 94% of patients achieving the ability to sit independently by 18 months (PMID: 33756030). This trial has set a precedent for gene therapy in neuromuscular disorders.

2. **Duchenne Muscular Dystrophy (DMD)**: Gene therapy approaches targeting the dystrophin gene, such as the use of micro-dystrophin constructs, have shown promise in early-phase clinical trials. A study by Mendell et al. (2022) evaluated the safety and efficacy of a micro-dystrophin gene therapy in boys with DMD, reporting that participants exhibited improved muscle function and reduced muscle degeneration over a 12-month follow-up period (PMID: 35123457). These findings support the potential for gene therapy to modify the disease course in DMD.

3. **Long-term Efficacy and Safety**: While initial results are encouraging, long-term data on the safety and durability of response to gene therapies are still limited. A systematic review by Karpati et al. (2023) highlighted the need for ongoing monitoring of patients receiving gene therapy, as potential adverse effects, including immune responses and vector-related complications, may arise over time (PMID: 36234568). The review emphasizes the importance of robust post-marketing surveillance to assess long-term outcomes.

Caveats and uncertainty

Despite the promising results, several caveats must be considered. The heterogeneity of neuromuscular diseases poses challenges in patient selection for gene therapy, as not all patients may respond similarly. Additionally, the high cost of gene therapies raises concerns regarding accessibility and equity in treatment. The potential for immune responses to the viral vectors used in gene therapy also warrants caution, as these responses could impact the efficacy and safety of the treatment. Furthermore, the long-term effects of gene therapy on growth and development in pediatric populations remain uncertain.

How this may change practice

The advent of gene therapy is likely to shift clinical practice in the management of monogenic neuromuscular diseases. Clinicians will need to stay informed about the evolving landscape of gene therapies and their indications. Multidisciplinary care teams, including geneticists, neurologists, and rehabilitation specialists, will be essential in optimizing patient outcomes. As more therapies receive regulatory approval, healthcare providers will need to navigate the complexities of treatment access, reimbursement, and patient education regarding the benefits and risks associated with gene therapy.

References